Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02563'
s EV-to-FCF Range Over the Past 10 Years
Min: -56.4 Med: -5.72 Max: -2.57
Current: -7.64
During the past 4 years, the highest EV-to-FCF of Beijing Biostar Pharmaceuticals Co was -2.57. The lowest was -56.40. And the median was -5.72.
HKSE:02563's EV-to-FCF is ranked worse than 100% of 341
companies
in the Biotechnology industry
Industry Median: 15.04
vs HKSE:02563: -7.64
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beijing Biostar Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Beijing Biostar Pharmaceuticals Co's share price for today is HK$3.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Biostar Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Beijing Biostar Pharmaceuticals Co EV-to-FCF Related Terms
Beijing Biostar Pharmaceuticals Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co EV-to-FCF Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EV-to-FCF
0.00
0.00
-38.57
-7.20
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
HKSE:02563 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's EV-to-FCF falls into.
Beijing Biostar Pharmaceuticals Co's current Enterprise Value is HK$874.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beijing Biostar Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-114.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a EV-to-FCF of -7.64 as of Aug. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #999999 out of 341 companies in the Biotechnology industry.
Is Beijing Biostar Pharmaceuticals Co's EV-to-FCF too high?
Beijing Biostar Pharmaceuticals Co's current EV-to-FCF is -7.64. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #999999 out of 341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #999999 out of 341 companies for EV-to-FCF. This places Beijing Biostar Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-FCF is 15.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.04, based on 341 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Biostar Pharmaceuticals Co's current EV-to-FCF is -7.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current EV-to-FCF of -7.64. The current EV-to-FCF is -7.64. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current EV-to-FCF is -7.64 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
